| Compounds | Topics | Title | Date |
|---|---|---|---|
| CBDV | anti-convulsant in mice | Cannabidivarin is anticonvulsant in mouse and rat | Dec 2012 |
|
Ingestion Method: 50-200 mg/kg These results indicate that CBDV is an effective anticonvulsant in a broad range of seizure models. Also it did not significantly affect normal motor function and, therefore, merits further investigation as a novel anti-epileptic in chronic epilepsy models. | |||
| CBD | anti-convulsant via review | Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis | Sept 2018 |
| Patients treated with CBD-rich extracts reported lower average dose (6.0 mg/kg/day) than those using purified CBD (25.3 mg/kg/day). The reports of mild (158/216, 76% vs. 148/447, 33%, p < 0.001) and severe (41/155, 26% vs. 23/328, 7%, p < 0.0001) adverse effects were more frequent in products containing purified CBD than in CBD-rich extracts. CBD-rich extracts seem to present a better therapeutic profile than purified CBD, at least in this population of patients with refractory epilepsy. | |||
| Linalool | anti-convulsant in vitro | anticonvulsant properties of linalool in glutamate-related seizure models. | May 1999 |
| The data indicate that linalool modulates glutamate activation expression in vitro (competitive antagonism of L-[3H]glutamate binding) and in vivo (delayed NMDA convulsions and blockage of QUIN convulsions). | |||
| H2CBD | anti-convulsant in rats | Synthetic, non-intoxicating 8,9-dihydrocannabidiol for the mitigation of seizures. | May 2019 |
| We describe here the anticonvulsant properties of 8,9-dihydrocannibidiol (H2CBD), a fully synthetic analogue of CBD that is prepared from inexpensive, non-cannabis derived precursors. H2CBD was found to have effectiveness comparable to CBD both for decreasing the number and reducing the severity of pentylenetetrazole-induced seizures in rats. | |||